Xifaxan
Product Images NDC 68258-1107

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 68258-1107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dispensing Solutions, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ndc 68258-1107-xx (Ndc 68258 1107 Xx Salix)

Ndc 68258-1107-xx (Ndc 68258 1107 Xx      Salix)
This is a description of two different pharmaceutical products. The first, a pink-colored round biconvex tablet with the inscription "SX", dispensed by Salix Pharmaceuticals, Inc. with the product ID 65649-0301-03, is to be taken orally according to the doctor's prescription. The second is Xifaxan 200 mg tablets with product #1107-X containing Rifamixin. They are packaged exclusively by Dispensing Solutions in Santa Ana, CA 92704, and are available in XX tablets, bearing lot number "SAMPLE EXP:00-00" and RX# 33710186. The tablets must be kept out of children's reach, and the storage temperature should be between 68°-77°F.*
FDA Label Image

Xifaxan Structural Formula (Xifaxan 1)

FDA Label Image

Kaplan-meier Event-free Curves Graph (Xifaxan 2)

FDA Label Image

Kaplan-meier Event-free Curves_pivotalhestudy (Xifaxan 3)

Kaplan-meier Event-free Curves_pivotalhestudy (Xifaxan 3)
This is a statistical report on a clinical trial comparing the effectiveness of a placebo treatment. The hazard ratio of the placebo treatment is reported to be 0.5, indicating a lower risk of the event in the placebo group compared to the other treatment group. The trial involved 954 participants and the logrank p-value was reported to be 0.0129, suggesting a significant difference between the placebo and other treatment groups. However, the remaining text appears to be incomplete or unreadable, except for the label "Days Post-randomization".*
FDA Label Image

Salix-logo (Xifaxan 4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.